CLINICAL_TRIALS
trial_result
· 2011-03-17
Clinical Trial Update: Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality [Phase 3]
Summary
A Phase 3 trial comparing lenalidomide to placebo in myelodysplastic syndromes with a deletion 5q abnormality has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene Corporation | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: COMPLETED | Results posted: 2011-03-17